- Home
- HOWL vs SRTS Comparison
HOWL vs SRTS Comparison
Compare HOWL & SRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- SRTS
- Stock Information
- Founded
- HOWL 2017
- SRTS 2010
- Country
- HOWL United States
- SRTS United States
- Employees
- HOWL N/A
- SRTS N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- SRTS Medical/Dental Instruments
- Sector
- HOWL Health Care
- SRTS Health Care
- Exchange
- HOWL Nasdaq
- SRTS Nasdaq
- Market Cap
- HOWL 64.5M
- SRTS 52.9M
- IPO Year
- HOWL 2021
- SRTS 2016
- Fundamental
- Price
- HOWL $0.99
- SRTS $4.14
- Analyst Decision
- HOWL Strong Buy
- SRTS Strong Buy
- Analyst Count
- HOWL 5
- SRTS 3
- Target Price
- HOWL $7.00
- SRTS $8.00
- AVG Volume (30 Days)
- HOWL 670.5K
- SRTS 172.7K
- Earning Date
- HOWL 11-04-2025
- SRTS 11-06-2025
- Dividend Yield
- HOWL N/A
- SRTS N/A
- EPS Growth
- HOWL N/A
- SRTS N/A
- EPS
- HOWL N/A
- SRTS N/A
- Revenue
- HOWL N/A
- SRTS $35,609,000.00
- Revenue This Year
- HOWL N/A
- SRTS N/A
- Revenue Next Year
- HOWL N/A
- SRTS $47.33
- P/E Ratio
- HOWL N/A
- SRTS N/A
- Revenue Growth
- HOWL N/A
- SRTS N/A
- 52 Week Low
- HOWL $0.60
- SRTS $3.03
- 52 Week High
- HOWL $2.38
- SRTS $9.31
- Technical
- Relative Strength Index (RSI)
- HOWL 37.92
- SRTS 57.25
- Support Level
- HOWL $0.80
- SRTS $3.81
- Resistance Level
- HOWL $1.03
- SRTS $4.34
- Average True Range (ATR)
- HOWL 0.10
- SRTS 0.35
- MACD
- HOWL 0.01
- SRTS -0.01
- Stochastic Oscillator
- HOWL 43.93
- SRTS 54.99
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.